IONS Ionis Pharmaceuticals Inc

$IONS well well, will you look at that. every single time i leave a board, the gains evaporate, vanquish, poof. Every time i post on a board, I bring future profits. Good news for you, i’m back. Starter again. Better open your heart and welcome me back.

$IONS Latest company news, Oct 20, 2026: GSK announced U.S. FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B, granted under Priority Review and Breakthrough Therapy designation. Ionis, which licensed bepirovirsen to GSK, is eligible for tiered royalties of 10% to 12% on net sales. More news in our $IONS stock hub on Merlintrader. Not investment advice.

$IONS I’ve been long here since it was ISIS before the name change. Could be over 10 years!

Next 3 weeks on the FDA calendar and it is not crowded. that is kind of the point Oct 26 $IONS bepirovirsen for chronic hepatitis B, B Well trials already showed functional cure after treatment stopped Oct 30 $INO INO 3107 for recurrent respiratory papillomatosis, accelerated approval path and inspections already done Nov 1 $AGIO mitapivat for sickle cell disease, a Sunday date so Friday is the practical window quiet on both sides of that little cluster imo. nobody is loud about any of these yet and yes, every one of these dates traces back to a company release or an SEC filing, not calendar gossip

$IONS Starting to lose patience. I swear they could come up with the cure for old age, and the stock would drop $5.

$IONS Bollinger bands are as tight as they've ever been. I expect the resolution from this price range within probably 2 or 3 days...

$IONS This just want to pop a hard on in your face. First stop 62.34. Then another at 83.92.

$IONS The sell-off this morning on very light volume... As a side note, ionis was ranked number one by Science as best employer in the industry, it was number two last year.

$IONS this gonna flip quicker than many think. Stars are aligning here and that drawdown was severely overdone Revs are there, and building.

$IONS Follow-up: Ionis Pharmaceuticals, an RNA-drug maker, saw partner GSK win FDA approval of hepatitis B drug Hibsago (bepirovirsen), whose label boxes hepatic flares and sudden, possibly life-threatening platelet drops, with weekly platelet checks. Ionis is eligible for tiered 10-12% royalties on GSK's net sales + undisclosed regulatory/sales milestones (upfront, license fee, earlier milestones paid) vs ~$7.54B value (16:00 ET Oct 20, 2026). Upside: 19% functional cure vs 0 of 614 on placebo. GSK expects more regulatory decisions in coming months.

$IONS Bounced off oversold and rounding out the bottom. Could get better as we assess the right side.

$IONS Ionis got two good pieces of news in about a day and the stock still closed down Friday. UBS upgraded it to Buy on Thursday and raised its target to 88 from 46. Then the CHMP recommended expanding TRYNGOLZA in the EU for severe hypertriglyceridemia (triglycerides at or above 880 mg/dL), ahead of the timeline Ionis had expected. Final European Commission decision is expected in Q4. The trial data behind it: placebo-adjusted triglyceride cuts of up to 72% at six months in CORE and CORE2, and an 85% reduction in acute pancreatitis events over 12 months pooled. One nuance on the EU piece: Sobi holds the commercialization rights outside the US, Canada and China, so for Ionis this is partner economics, not direct EU sales. Stock closed Friday at 42.94, down 2.7%, down about 46% year to date and pretty close to the 52-week low of 42.08.

$IONS Follow-up: Roche's sefaxersen cut IgA nephropathy proteinuria 43.1% vs placebo at 37 weeks. 🏢 Ionis Pharmaceuticals, an RNA-drug maker worth ~$7.12B ($42.84, 13:49 ET Oct 23, 2026), licensed kidney drug sefaxersen to Roche, and its September 23, 2026 8-K said only that the Phase 3 IMAgINATION study met its primary endpoint, with no effect size 📈 Roche's ASN Kidney Week 2026 data now put that effect at a 43.1% cut in proteinuria versus placebo at 37 weeks (95% CI 32.5-52.0, P<0.0001), on 24-hour urine protein-to-creatinine ratio ⚠️ The bear case is that a 37-week proteinuria drop is a stand-in measure, and the study stays blinded until kidney function (eGFR) is read at week 105 📅 Next: Roche will share the data with health authorities; the blinded study runs to an eGFR readout at week 105, and no filing date is given Source: SEC 8-K, Oct 23 + SEC 8-K, Sep 23

$IONS The company is currently studying the treatment, called ION337, in the Phase 1/2 Ascend trial. Ionis recently got FDA approval for Zanvastro, a treatment for Alexander disease

$IONS BMO analyst David Leibowitz upgrades ionis from market perform to outperform and raises the price Target from $54 to $66.

$IONS I was expecting more from pre-market. On the other hand this has proven to be a stable stock. Any insight to why this didn't jump on approval?

Latest company news, October 16, 2026: Ionis and partner Sobi said the EMA's CHMP recommended extending the EU indication of TRYNGOLZA (olezarsen) to adults with severe hypertriglyceridemia (fasting TG of 880 mg/dL or higher), based on Phase 3 CORE and CORE2. Not yet an approval: the European Commission decision is expected in Q4 2026. $IONS Details on our site. Not investment advice.

$IONS Ionis Pharmaceuticals, an RNA-drug maker: the EU CHMP nod for TRYNGOLZA in severe hypertriglyceridemia covers only adults with triglycerides ≥880 mg/dL, about 700,000 of ~2 million EU5 patients, narrower than its US label at ≥500. Partner Sobi sells it in the EU; Ionis gets milestones and tiered royalties up to the mid-20% range on net sales. No amounts or EU sales forecasts are given to size vs a ~$7.33B market value ($44.12, 16:00 ET Oct 15, 2026). Upside: the opinion came ahead of schedule. European Commission decision expected in Q4 2026.

Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment $IONS $XBI https://stocktwits.com/news/equity/markets/ionis-pharmaceuticals-secures-fda-orphan-drug-designation-for-rare-epilepsy-treatment/cZxw0yGRBDO

📅 CATALYST REMINDER | $IONS October 26, 2026 — FDA PDUFA Bepirovirsen (GSK/Ionis) has an FDA target action date for chronic hepatitis B. The scheduled decision is not a guarantee of approval. More details in our hub. #IONS #Biotech #FDA #PDUFA